Why Hasn't Asthma Mortality Improved Despite Decades of Better Drugs?
Inhaled corticosteroids, better beta-agonists, biologics for severe disease — asthma pharmacotherapy has genuinely advanced for decades. Mortality hasn't followed the same curve. The gap isn't a drug problem. It's an identification problem.
If better medications reliably translated into fewer deaths, asthma mortality should have fallen steadily alongside the pharmacology. It hasn't. Mortality trends have plateaued in recent decades despite improved pharmacotherapy — and the reason isn't that the drugs stopped working. It's that the patients who die from asthma are disproportionately not the ones benefiting from those improvements in the first place.
The Strongest Predictor Isn't a Drug Response — It's History
Among the risk factors for near-fatal or fatal asthma exacerbations, one stands out as the single strongest predictor: a prior intubation for asthma. A patient with that history has already demonstrated that their physiology can decompensate catastrophically and rapidly — not as a hypothetical risk, but as a documented fact about how their disease behaves under stress. That's a fundamentally different kind of information than anything a spirometer or a symptom questionnaire captures in the moment.
The Systemic Failure
High-risk patients remain under-identified and under-treated in the out-of-hospital environment. That's the mechanism behind the plateau, stated directly: the tools to manage severe asthma have improved, but the system's ability to flag who needs those tools most intensively, before the crisis, hasn't kept pace. A patient with a chronically under-treated disease, poor self-management, and limited access to preventive care can be sitting on the same near-fatal risk profile as someone with a documented ICU history — and show up to an emergency encounter having never been flagged as high-risk by anyone.
What This Means at the Point of Care
A patient's oxygen saturation and work of breathing tell you how sick they are right now. Their history of prior near-fatal episodes tells you something the current exam can't: how fast and how far this particular patient's physiology is capable of dropping. Two patients presenting with identical vital signs are not the same risk if one has a prior asthma intubation on record and the other doesn't — and treating them identically because their numbers currently match is a blind spot that we see in the mortality plateau.
The Takeaway
Asthma pharmacology solved a drug-availability problem decades ago. What it hasn't solved, and what better drugs can't solve on their own, is a recognition problem — identifying, before the crisis, which patients are carrying the highest risk of a catastrophic and rapid decompensation. That's a history question, not a prescription question, which is exactly why better medicine is more than just better pharmacology.